Weekly epirubicin plus lonidamine in advanced breast carcinoma

Breast Cancer Research and Treatment

Volumn 56, Issue 3, 1999, Pages 233-237

  Nisticò, Cecilia ^a   Garufi, Carlo ^a   Milella, Michele ^a   D'Ottavio, Anna Maria ^a   Vaccaro, Angela ^a   Fabi, Alessandra ^a   Terzoli, Edmondo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Advanced breast cancer; Epirubicin; Lonidamine; Weekly schedule

Indexed keywords

EPIRUBICIN; LONIDAMINE;

ALOPECIA; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MYALGIA; MYCOSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VOMITING;

EID: 0032751627     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1006213815195     Document Type: Article

References (29)

1. Jensen OM, Esteve J, Moller H, Renard H: Cancer in the European Community and its member states. Eur J Cancer 26: 1167-1256, 1993
2. Clark GM, Sledge GW Jr, Osborne CK, McGuire WL: Survival from first recurrences: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin. Oncol 1: 55-61 1987
3. Hortobagyi GN: Treatment of breast cancer. N Engl J Med 339: 974-984, 1998
4. Harris JR, Morrow M, Norton L: Malignant tumors of the breast. In: De Vita VT Jr, Helman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. JB Lippincott, Philadelphia, 1997, pp 1557-1616
5. Twelves CJ, Dobbs NA, Aldhous M, Harper PG, Rubens D, Richards MA: Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer Chemother Pharmacol 28: 302-307, 1991
6. Floridi A, Paggi MG, Marcante ML, Sivestrini B, Caputo A, De Martino C: Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cell. J Natl Cancer Inst 66: 497-499, 1981
7. Floridi A, Paggi MG, D'Atri S, De Martino C, Marcante ML, Silvestrini B, Caputo A: Effect of Ionidamine on the energy metabolism of Erlich ascites tumor cells. Cancer Res 41: 4661-4666, 1981
8. De Martino C, Malorni W, Accinni L, Rosati F, Nista A, Formisano G, Silvestrini B, Arancia G: Cell membrane changes induced by Ionidamine in human erythrocytes and T lymphocytes and Erlich ascites tumor cells. Exp Mol Path 46: 15-30, 1987
9. Citro G, Cucco C, Verdina A, Zupi G: Reversal of adriamycin resistance by Ionidamine in human breast cancer subline. Br J Cancer 64: 534-536, 1991
10. Savini S, Zoli W, Nanni O, Volpi A, Frassinetti GL, Magni E, Flamigni A, Amadori A, Amadori D: In vitro potentiation by Ionidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines. Br Cancer Res Treat 24: 27-34, 1992
11. Silvestrini R, Zaffaroni N, Villa R, Orlandi R, Costa A: Enhancement of Cisplatin activity by Ionidamine in human ovarian cancer cells. Int J Cancer 52: 813-817, 1992
12. Del Bufalo D, Zupi G: In vitro potentiation of epirubicin activity by Ionidamine in a human breast cancer cell line. Int Oncol 4: 737-740, 1994
13. Pronzato P, Amoroso D, Bertelli G Conte PF, Cusimano MP Ciottoli GB, Gulisano M, Lionetto R, Rosso R: Phase II study of Ionidamine in metastatic breast cancer. Br J Cancer 59: 251-253, 1989
14. Scott J, Huskisson EC: Graphic representation of pain. Pain 2: 175-184, 1976
15. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
16. Robustelli della Cuna G, Pedrazzoli P: Toxicity and clinical tolerance of Ionidamine. Semin Oncol 18(Suppl 4): 18-22, 1991
17. Calabresi F: Drug resistance: Ionidamine. Principles and Practice of Oncology Updates 8: 1-15, 1994
18. Perez DJ, Harvey VJ, Robinson BA, Atkinson CH, Dady PJ, Kirk AR, Evans BD, Chapman PJ: A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 9: 2148-2152, 1991
19. Jain KK, Casper ES, Geller NL, Hakes TB, Kaufman RJ, Curie V, Schwartz W, Cassidy C, Petroni GR, Young CW: A prospective randomized comparison or epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3: 818-826, 1985
20. Hortobagyi GN, Yap HY, Kau SW, Fraschini G, Ewer MS, Chawla SP, Benjamin RS: A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol 12: 57-62, 1989
21. Beretta G, Locatelli C, Tabiadon D, Labianca R, Fraschini P, Luporini G: Epirubicin treatment of advanced breast carcinoma with the weekly low-dose regimen. Oncology 44: 6-12, 1987
22. Barni S, Archili S, Lissoni P, Paolorossi F, Crispino S, Tancini G: A weekly schedule of Epirubicin in pretreated advanced breast cancer. Tumori 79: 45-48, 1993
23. Moraglio L, Brema F, Pastorino G, Martini MC, Vallauri M: Combination of epirubicin and Ionidamine for treatment of advanced breast cancer. Tumori 81: 107-111, 1995
24. Gardin G, Barone C, Nascimben O, Ianniello G, Sturba F, Contu A, Pronzato P, Rosso R: Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. A phase II study. Eur J Cancer 32A: 176-177, 1996
25. Dogliotti L, Berruti A, Buniva T, Zola P, Baù MG, Farris A, Sarobba MG, Bottini A, Alquati P, Deltetto F, Gosso P, Monzeglio C, Moro G, Sussio M and Perroni D. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. J Clin Oncol 14: 1165-1172, 1996
26. Calabresi F, Di Lauro L, Marolla P, Gallocurcio C, Paoletti G, Calabrò A, Giannarelli D, Ballatore P, Foggi CM, Di Palma M, Stolfi R, Cortesi E: Fluorouracil, doxorubicin and cyclophosphamide plus Ionidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study. Semin Oncol 2(Suppl 4): 66-72, 1991
27. Amadori D, Frassineti GL, De Matteis A, Mustacchi G, Santoro A, Cariello S, Ferrari M, Nascimben O, Nanni O, Lombardi A, Scarpi E, Zoli W: Modulating effect of Ionidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial. Breast Cancer Res Treat 49: 209-217, 1998
28. Tomirotti M, Bernardo G, Epifani C, Biasioli R, Franchi R, Mensi F, Carnaghi P, Schieppati G, Scanni A: Recovery of response to adriamycin and cyclophosphamide by Ionidamine in previously treated metastatic breast cancer patients. Int J Oncol 3: 213-217, 1993
29. Norton L: Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 24(4 Suppl 10): 3-10, 1997